Welcome back to another edition of Endpoints Weekly. We’re barreling toward the holiday season, which means it’s time for an early programming note: Our newsletters
Eligible health centers purchased $81.4 billion in discounted drugs under the federal 340B program in 2024, an increase of 23% from the previous year as
An FDA staff analysis of the safety of pediatric Covid-19 shots has been finalized and sent to the agency’s vaccine and biologics head Vinay Prasad.
Health insurers are facing two colliding forces heading into 2026: Medical costs are challenging the way they do business, and major technology shifts are finally
As part of a batch of recommendations issued Friday, the European Medicines Agency’s human medicines committee (CHMP) recommended rejecting Anavex’s Alzheimer’s disease drug, issuing a
A new guidance document issued by the FDA this week offers recommendations for how makers of prescription biosimilars and biologic reference products should approach promotional advertising and labeling for those meds.
Copyright 2025 dijee Intelligence Ltd. dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registeration number 16808844